Viagra 50mg 50tabs

Viagra 75mg (Sildenafil) 50 Tablets | iRoids Pharma

Viagra 75mg is an oral phosphodiesterase type 5 inhibitor containing 75mg of Sildenafil Citrate per tablet, available in packs of 50 tablets. At iRoids Pharma, we carry Viagra 75mg as part of our sexual health compound inventory for customers in markets where Sildenafil is legally available.

Sildenafil Citrate is the active compound in this preparation, universally recognized under the brand name Viagra. It is one of the most extensively researched and clinically documented pharmaceutical compounds in modern medicine, carrying active FDA approval for erectile dysfunction and pulmonary arterial hypertension. Sildenafil’s pharmacological profile, mechanism of action, and clinical safety data are among the most thoroughly characterized of any compound in its drug class.

The 75mg tablet format occupies a specific position within the Sildenafil concentration landscape that requires direct discussion. Pharmaceutical grade Viagra by Pfizer is produced at 25mg, 50mg, and 100mg tablet formats. The 75mg concentration consequently falls between the standard 50mg and 100mg pharmaceutical clinical formats. This page covers the pharmacology, concentration-specific considerations, clinical background, and health and legal context relevant to anyone researching Sildenafil at iRoids Pharma. It does not constitute medical advice, recommend use outside of physician supervision, or provide dosage guidance of any kind.

Product Specifications

The 75mg Format: Position Within the Sildenafil Concentration Landscape

The 75mg per tablet concentration of this preparation carries specific significance that distinguishes it from both the standard pharmaceutical clinical formats and the non-prescription market context for Sildenafil.

Relationship to Standard Pharmaceutical Formats

Pharmaceutical grade Viagra by Pfizer is produced at 25mg, 50mg, and 100mg tablet formats. The 75mg concentration sits precisely between the 50mg and 100mg standard pharmaceutical clinical formats. It is consequently 50 percent higher per tablet than the standard 50mg starting format and 25 percent lower per tablet than the maximum standard 100mg format. The 75mg concentration does not correspond to any standard pharmaceutical clinical tablet format produced by Pfizer or any other major branded Sildenafil manufacturer.

Clinical Research Applicability

The controlled clinical research base for Sildenafil was established primarily at the 25mg, 50mg, and 100mg standard pharmaceutical formats. The 75mg concentration consequently falls outside the discrete clinical dose units that the primary Sildenafil clinical trials directly characterized. Clinical research at 50mg and 100mg provides the most directly applicable reference for the pharmacological effects and side effect profile at 75mg. The dose-dependent pharmacological effects of Sildenafil at 75mg are consequently interpolatable from the clinical literature at these adjacent standard formats but are not directly characterized in the controlled research base as a discrete clinical dosing unit.

Practical Positioning

The 75mg format provides a specific per-tablet Sildenafil concentration that is unavailable in standard pharmaceutical Viagra tablet ranges. It delivers 50 percent more active compound per tablet than the standard 50mg format and 25 percent less active compound per tablet than the maximum standard 100mg format. For anyone researching Sildenafil at a concentration between the standard 50mg and 100mg pharmaceutical reference points, the 75mg format consequently provides a concentration option that the standard pharmaceutical tablet range does not offer.

50 Tablet Pack Context

Each pack contains 50 tablets at 75mg per tablet, providing a total of 3750mg of active Sildenafil Citrate per pack. This pack size provides a substantial total supply compared to standard pharmaceutical Viagra packaging, which typically contains 4 to 12 tablets per pack. The 50 tablet non-prescription format consequently represents a significantly larger total supply than standard pharmaceutical packaging configurations.

What Is Sildenafil

Sildenafil Citrate is a synthetic compound developed by Pfizer researchers originally as a potential cardiovascular medication for angina pectoris. Clinical trials in the late 1980s and early 1990s revealed its pronounced effects on penile erection as an unexpected but clinically significant finding. Pfizer subsequently redirected its clinical development toward erectile dysfunction, and the FDA approved Sildenafil under the Viagra brand name in 1998 for the treatment of erectile dysfunction in men. This approval represented the first oral pharmaceutical treatment specifically approved for erectile dysfunction and fundamentally changed the clinical management of this condition.

Structurally, Sildenafil is a pyrimidinone derivative that selectively inhibits the phosphodiesterase type 5 enzyme. This selective inhibition is the mechanistic basis for all of Sildenafil’s primary pharmacological effects. The compound’s selectivity for PDE5 over other phosphodiesterase enzyme subtypes is the pharmacological foundation for its clinical utility and its tolerability profile compared to less selective phosphodiesterase inhibitors.

The compound received a second FDA approval in 2005 under the brand name Revatio for the treatment of pulmonary arterial hypertension. This second approved indication, which uses Sildenafil at lower doses than the erectile dysfunction indication, reflects the compound’s vasodilatory effects in pulmonary vasculature through the same PDE5 inhibitory mechanism that drives its erectile dysfunction efficacy.

How Sildenafil Works

Sildenafil’s pharmacological mechanism operates through selective inhibition of the phosphodiesterase type 5 enzyme in smooth muscle tissue, particularly in the corpus cavernosum of the penis and in pulmonary vascular smooth muscle.

PDE5 Inhibition Mechanism

Sexual stimulation triggers the release of nitric oxide from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates guanylate cyclase, which increases production of cyclic guanosine monophosphate, designated cGMP. Elevated cGMP levels produce smooth muscle relaxation in the corpus cavernosum, allowing increased blood flow into penile tissue and producing erection. The phosphodiesterase type 5 enzyme normally breaks down cGMP, limiting the duration and magnitude of smooth muscle relaxation. Sildenafil inhibits PDE5, consequently preventing cGMP breakdown and allowing cGMP to accumulate to levels sufficient for smooth muscle relaxation and penile blood flow.

This mechanism requires the presence of sexual stimulation and nitric oxide release as a prerequisite for pharmacological effect. Sildenafil does not directly produce erection in the absence of sexual stimulation. It potentiates the natural erectile response by preventing the enzymatic degradation of the cGMP signal generated by sexual stimulation. This stimulation-dependent mechanism is a fundamental pharmacological characteristic that distinguishes Sildenafil from compounds that produce direct smooth muscle relaxation regardless of stimulation state.

Selectivity for PDE5

Sildenafil demonstrates selectivity for PDE5 over other phosphodiesterase enzyme subtypes. This selectivity is quantified through inhibitory concentration ratios comparing its potency against PDE5 to its potency against other PDE subtypes including PDE1, PDE2, PDE3, PDE4, and PDE6. The selectivity for PDE5 over PDE3, which is expressed in cardiac muscle, is particularly relevant to cardiovascular safety considerations. The limited inhibition of PDE6, which is expressed in retinal photoreceptors, is directly relevant to the visual disturbances reported as a dose-dependent side effect with Sildenafil use.

Vasodilatory Effects

PDE5 inhibition by Sildenafil produces vasodilatory effects in vascular smooth muscle throughout the body, not exclusively in penile tissue. These systemic vasodilatory effects are responsible for the blood pressure reduction associated with Sildenafil use and are directly relevant to its pharmacological interaction with nitrate medications. The vasodilatory effects in pulmonary vasculature underlie Sildenafil’s approved clinical application in pulmonary arterial hypertension.

Onset and Duration at the 75mg Concentration

Sildenafil produces onset of action approximately 30 to 60 minutes following oral administration. Peak plasma concentrations are typically reached within 60 minutes of administration on an empty stomach. High-fat meals delay absorption and reduce peak plasma concentrations. At the 75mg concentration, peak plasma concentrations are proportionally higher than at the standard 50mg format and proportionally lower than at the standard 100mg format. Duration of pharmacological effect is approximately 4 to 6 hours across all standard clinical concentration formats.

Clinical Background

Sildenafil carries one of the most extensively documented clinical histories of any pharmaceutical compound, supported by the largest clinical trial program ever conducted for an erectile dysfunction medication at the time of its approval.

FDA Approval for Erectile Dysfunction

The FDA approved Sildenafil under the Viagra brand name in March 1998 for the treatment of erectile dysfunction in men. This approval was based on an extensive clinical trial program demonstrating efficacy across multiple erectile dysfunction etiologies including psychogenic, organic, and mixed etiology presentations. The clinical trial program established the 25mg, 50mg, and 100mg dose-response relationship that defines the pharmaceutical clinical reference for Sildenafil’s pharmacological profile.

FDA Approval for Pulmonary Arterial Hypertension

The FDA approved Sildenafil under the Revatio brand name in 2005 for the treatment of pulmonary arterial hypertension. This second approval at lower doses than the erectile dysfunction indication reflects Sildenafil’s vasodilatory effects in pulmonary vasculature and provides an additional clinical research context for its pharmacological mechanism beyond the erectile dysfunction indication.

Post-Marketing Safety Data

The extensive post-marketing surveillance data accumulated since Sildenafil’s 1998 approval represents one of the largest real-world safety datasets for any pharmaceutical compound in history. This post-marketing data provides a comprehensive characterization of Sildenafil’s safety profile across the full range of ages, comorbidities, and concomitant medications encountered in clinical practice. The cardiovascular safety data, drug interaction profile, and visual side effect documentation accumulated over more than two decades of post-marketing surveillance are directly relevant to understanding the risk profile of the 75mg iRoids Pharma preparation.

Comparative Research With Other PDE5 Inhibitors

Extensive comparative clinical research has examined Sildenafil alongside other PDE5 inhibitors including Tadalafil and Vardenafil across efficacy, onset, duration, and side effect parameters. This comparative literature provides a relevant context for understanding Sildenafil’s pharmacological position within the PDE5 inhibitor class and its practical distinctions from longer-acting alternatives.

Sildenafil 75mg Versus Other Sexual Health and Vasoactive Compounds at iRoids Pharma

Versus Sildenafil 100mg

The standard 100mg maximum pharmaceutical clinical format for Sildenafil delivers 33 percent more active compound per tablet than the 75mg iRoids Pharma preparation. Every dose-dependent pharmacological effect including erectile response enhancement and dose-dependent side effects is consequently more pronounced per tablet at the 100mg concentration. The 75mg format provides a per-tablet concentration between the standard 50mg and 100mg clinical reference points, offering a middle-ground option unavailable in the standard pharmaceutical tablet range.

Versus Tadalafil

Tadalafil is a PDE5 inhibitor sharing the same primary mechanism as Sildenafil but with a significantly longer half-life of approximately 17 to 18 hours. This extended half-life produces a duration of effect of up to 36 hours compared to Sildenafil’s 4 to 6 hours. Tadalafil is consequently preferred in clinical discussions where extended duration of effect is a primary consideration. Sildenafil’s shorter half-life produces a more concentrated pharmacological effect window with faster onset and more predictable timing compared to Tadalafil’s extended duration profile.

Versus Vardenafil

Vardenafil is a non-steroidal PDE5 inhibitor with a pharmacological profile similar to Sildenafil in terms of onset and duration. Vardenafil demonstrates slightly higher potency against PDE5 than Sildenafil on a milligram-per-milligram basis. Both compounds produce similar clinical efficacy profiles in comparative erectile dysfunction trials. The practical distinctions between Sildenafil and Vardenafil are consequently less pronounced than the distinctions between either compound and the longer-acting Tadalafil.

Side Effects and Health Risks

Sildenafil 75mg carries a well-documented side effect profile based on the most extensive clinical trial dataset and post-marketing surveillance of any PDE5 inhibitor. The 75mg concentration produces dose-dependent side effects that are proportionally greater per tablet than at the standard 50mg format and proportionally less than at the standard 100mg format.

Cardiovascular Effects

The most serious health considerations associated with Sildenafil use are cardiovascular in nature. Sildenafil’s vasodilatory mechanism produces a reduction in systemic blood pressure from PDE5 inhibition in vascular smooth muscle throughout the body. This blood pressure reduction is clinically manageable in otherwise healthy individuals. However, it becomes potentially life-threatening when Sildenafil is combined with nitrate medications including nitroglycerin, isosorbide mononitrate, and isosorbide dinitrate, or with nitric oxide donors. The combination of Sildenafil with any nitrate medication produces a severe and potentially fatal additive hypotensive effect. This interaction is the most critical contraindication associated with Sildenafil use and applies absolutely at any concentration.

Men with pre-existing cardiovascular conditions including uncontrolled hypertension, recent myocardial infarction, unstable angina, or severe heart failure should not use Sildenafil without direct physician supervision regardless of the concentration format. The cardiovascular demands of sexual activity combined with Sildenafil’s vasodilatory effects represent a meaningful clinical consideration for men with compromised cardiovascular reserve.

Visual Disturbances

Sildenafil produces dose-dependent visual disturbances including altered color perception described as a blue-green tinge, increased light sensitivity, and blurred vision. These effects relate to mild inhibition of PDE6 in retinal photoreceptors. At the 75mg concentration, visual disturbance effects are proportionally more pronounced than at the standard 50mg format. These effects are transient and resolve as plasma concentrations decline. However, rare cases of non-arteritic anterior ischemic optic neuropathy have been reported in association with PDE5 inhibitor use, representing a more serious but uncommon visual consideration.

Headache and Flushing

Headache and facial flushing are the most consistently reported common side effects across all Sildenafil clinical trials at all concentrations. These effects result from systemic vasodilation and are dose-dependent, consequently more pronounced at 75mg per tablet than at the standard 50mg format. Nasal congestion from vasodilatory effects on nasal mucosa is a related commonly reported side effect.

Hypotension

Orthostatic hypotension and symptomatic blood pressure reduction are dose-dependent side effects more pronounced at the 75mg concentration than at the standard 50mg format. These effects are more clinically significant in patients taking alpha-blocker medications for hypertension or benign prostatic hyperplasia, where additive hypotensive effects from the combination produce clinically significant blood pressure reduction. Alpha-blocker use consequently requires specific medical consideration before any Sildenafil use.

Drug Interactions

Sildenafil’s metabolism through the CYP3A4 hepatic enzyme pathway produces clinically significant drug interactions with CYP3A4 inhibitors including certain antifungal medications, HIV protease inhibitors, and certain macrolide antibiotics. These drug interactions increase Sildenafil plasma concentrations and consequently amplify both efficacy and side effects in an unpredictable manner. CYP3A4 inducers reduce Sildenafil plasma concentrations. Anyone using medications processed through CYP3A4 pathways should consequently consult a physician before using Sildenafil at any concentration.

Priapism

Prolonged erection lasting more than four hours, designated priapism, is a rare but serious adverse effect associated with PDE5 inhibitor use including Sildenafil. Priapism requires immediate medical intervention to prevent permanent erectile tissue damage. Men with conditions predisposing to priapism including sickle cell anemia, multiple myeloma, and leukemia face elevated risk and should consequently not use Sildenafil without direct physician supervision.

Legal and Regulatory Status

Sildenafil is a prescription-only medication in the United States under the Viagra brand name for erectile dysfunction and the Revatio brand name for pulmonary arterial hypertension. Generic Sildenafil became available in the United States in 2017 following patent expiration and is widely available through prescription channels. Obtaining Sildenafil without a valid prescription is a legal offense in the United States.

In the United Kingdom, Sildenafil became available over the counter in 2018 under the brand name Viagra Connect at the 50mg concentration for men over 18 years following regulatory reclassification. Higher concentration formats including the 75mg non-prescription format remain outside standard UK over-the-counter availability.

The World Anti-Doping Agency does not currently ban Sildenafil in most competitive sports contexts. However, specific sporting organizations may carry their own restrictions. You are responsible for confirming the regulatory status in your specific sporting context if applicable.

You are responsible for confirming the legal status of Sildenafil in your specific jurisdiction before purchasing from iRoids Pharma.

Frequently Asked Questions

Is Viagra 75mg Available at iRoids Pharma

Yes. iRoids Pharma carries Viagra 75mg in packs of 50 tablets for customers in markets where Sildenafil is legally available. Visit iroidspharma.com to check current availability and pricing.

What Is the Half-Life of Sildenafil

Sildenafil produces a half-life of approximately 3 to 5 hours. This relatively short half-life produces a concentrated pharmacological effect window of approximately 4 to 6 hours following administration. Onset of action occurs approximately 30 to 60 minutes following oral administration on an empty stomach.

Does Sildenafil Work Without Sexual Stimulation

No. Sildenafil potentiates the natural erectile response by preventing enzymatic degradation of the cGMP signal generated by sexual stimulation. It does not directly produce erection in the absence of sexual stimulation. The presence of sexual stimulation and the resulting nitric oxide release are prerequisites for Sildenafil’s pharmacological mechanism to produce its erectile effects.

Why Is the 75mg Format Not a Standard Pharmaceutical Tablet Format

Pharmaceutical grade Viagra by Pfizer is produced at 25mg, 50mg, and 100mg tablet formats. The 75mg concentration sits between the 50mg and 100mg standard pharmaceutical formats and does not correspond to any standard commercial pharmaceutical tablet format. It is available at iRoids Pharma as a non-prescription preparation for markets where Sildenafil is legally obtainable outside of prescription channels.

Is It Safe to Take Sildenafil With Nitrate Medications

No. Combining Sildenafil with any nitrate medication produces a severe and potentially fatal additive hypotensive effect. This combination is an absolute contraindication at any Sildenafil concentration. Anyone taking nitrate medications for cardiovascular conditions must not use Sildenafil under any circumstances without direct physician evaluation and guidance.

How Does the 75mg Format Compare to the Standard 50mg and 100mg Pharmaceutical Formats

The 75mg format delivers 50 percent more active compound per tablet than the standard 50mg pharmaceutical format and 25 percent less active compound per tablet than the standard 100mg format. It consequently occupies a middle position between these two standard pharmaceutical reference points. Every dose-dependent pharmacological effect and side effect is proportionally positioned between the 50mg and 100mg clinical reference data.

What Are the Most Serious Health Risks

The absolute contraindication with nitrate medications represents the most serious safety consideration associated with Sildenafil use at any concentration. Cardiovascular effects in men with pre-existing cardiovascular conditions, drug interactions through the CYP3A4 pathway, visual disturbances including rare cases of ischemic optic neuropathy, and priapism in predisposed individuals complete the primary risk profile. Medical supervision is consequently strongly recommended for anyone considering Sildenafil use at any concentration.

How Does Sildenafil Differ From Tadalafil

Sildenafil produces a half-life of approximately 3 to 5 hours with a duration of effect of approximately 4 to 6 hours. Tadalafil produces a half-life of approximately 17 to 18 hours with a duration of effect of up to 36 hours. Both compounds work through PDE5 inhibition but their duration profiles are fundamentally different. Sildenafil produces a more concentrated and time-limited pharmacological effect window. Tadalafil produces an extended effect duration that extends well beyond the immediate post-administration period.

Is Viagra 75mg Legal to Purchase

Sildenafil is prescription-only in the United States and most developed countries. Legal status varies by jurisdiction. You are consequently responsible for confirming the legal status in your jurisdiction before purchasing from iRoids Pharma.

What to Consider Before Purchasing Viagra 75mg

Sildenafil carries one of the most extensively documented pharmacological profiles and safety records of any pharmaceutical compound in modern medicine. Its multiple FDA-approved indications, the largest erectile dysfunction clinical trial program in pharmaceutical history, and more than two decades of post-marketing safety surveillance provide a comprehensive pharmacological reference that few other compounds can match in terms of controlled research depth and real-world safety characterization.

The 75mg format at iRoids Pharma sits between the standard 50mg and 100mg pharmaceutical clinical formats and does not correspond to any standard commercial pharmaceutical tablet format. The clinical research base established at 50mg and 100mg provides the most directly applicable pharmacological reference for the 75mg concentration through interpolation between these adjacent standard clinical data points.

The absolute contraindication with nitrate medications represents the most critical safety consideration associated with Sildenafil use at any concentration and applies with equal force to the Viagra 75mg Sildenafil iRoids Pharma preparation. Anyone taking nitrate medications for any indication must not use this preparation under any circumstances.

The iRoids Pharma non-prescription preparation does not carry the manufacturing oversight of pharmaceutical grade Viagra by Pfizer. The clinical research base applies to the pharmacological and risk profile of the active compound regardless of the specific manufacturer. Manufacturing standards and quality verification consequently differ between pharmaceutical grade and non-prescription preparations.

Sildenafil carries documented cardiovascular, visual, hypotensive, drug interaction, and priapism-related health risks that require medical supervision to manage responsibly. Consulting a licensed medical professional is consequently the appropriate starting point for anyone with health concerns related to PDE5 inhibitor use at any concentration.

For customers in markets where Sildenafil is legally available, visit iroidspharma.com to check current Viagra 75mg availability, pricing, and stock levels.